Emergent BioSolutions Inc. - Form 8-K Summary
Business Context and Reporting Period
Company: Emergent BioSolutions Inc.
Filing Date: July 13, 2020
Reporting Period: Current report for the event date of July 13, 2020.
Context: The filing reports a significant contract modification under Item 8.01 (Other Events) related to the procurement of anthrax vaccine doses for the U.S. Strategic National Stockpile.
Key Financial Metrics
This filing is a current report regarding a specific event and does not contain comprehensive financial statements (e.g., revenue, profit, cash flow, margins, debt, or liquidity) for a reporting period. The only specific financial figure disclosed is the value of the contract option exercised.
- Contract Value: $258 million
- Product: AV7909 (anthrax vaccine adsorbed with adjuvant)
- Delivery Timeline: Over 12 months
Material Changes
The material change reported is the exercise of an option under the existing BARDA AV7909 Contract (effective September 30, 2016). Emergent received Modification No. 6 from the Office of the Assistant Secretary for Preparedness and Response (ASPR), an agency of the U.S. Department of Health and Human Services. This modification secures funding for additional vaccine doses to be delivered to the Strategic National Stockpile.
Guidance, Outlook, and Risks
Management Commentary: The filing confirms the receipt of the contract modification but does not provide updated financial guidance or outlook beyond the specific contract value.
Contingencies: The full text of Modification No. 6, containing redacted confidential information, is expected to be filed as an exhibit to the Form 10-Q for the fiscal quarter ended September 30, 2020.
Risks: The filing notes that the description of the modification is qualified by reference to the full text of the agreement.
Key Facts for Investor Verification
- Verify the total value of $258 million for the AV7909 contract option.
- Confirm the 12-month delivery schedule for the Strategic National Stockpile.
- Review the full text of Modification No. 6 when filed as an exhibit to the Q3 2020 Form 10-Q for detailed terms and redactions.
- Check the original BARDA AV7909 Contract (Exhibit 10.48 to the 2018 Form 10-K) to understand the base agreement terms.